Publications
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | First Faculty of Medicine
- Cortical Pathology in Multiple Sclerosis - Morphology, Immunopathology and Clinical Context2012 | First Faculty of Medicine
- Fingolimod (drug)2011 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?2011 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient?2011 | First Faculty of Medicine
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study2009 | First Faculty of Medicine
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis2008 | First Faculty of Medicine
Loading network view...